TD Asset Management Inc. cut its position in Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 8.5% during the first quarter, Holdings Channel reports. The fund owned 14,000 shares of the biopharmaceutical company’s stock after selling 1,300 shares during the period. TD Asset Management Inc.’s holdings in Intra-Cellular Therapies were worth $228,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ITCI. Pacad Investment Ltd. acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $130,000. Highbridge Capital Management LLC acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $166,000. Boothbay Fund Management LLC acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $186,000. Bayesian Capital Management LP acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $213,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $239,000. Institutional investors and hedge funds own 68.55% of the company’s stock.

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) opened at 10.50 on Friday. The company’s market cap is $455.91 million. The firm’s 50 day moving average is $10.41 and its 200 day moving average is $13.50. Intra-Cellular Therapies Inc. has a 12-month low of $7.85 and a 12-month high of $45.20.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.12. Intra-Cellular Therapies had a negative net margin of 27,180.94% and a negative return on equity of 29.74%. The company had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.02 million. During the same quarter in the previous year, the company earned ($0.64) earnings per share. Equities research analysts anticipate that Intra-Cellular Therapies Inc. will post ($3.03) EPS for the current fiscal year.

WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.dailypolitical.com/2017/06/16/td-asset-management-inc-sells-1300-shares-of-intra-cellular-therapies-inc-itci.html.

A number of equities research analysts have issued reports on the company. Zacks Investment Research upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research note on Tuesday, May 16th. Leerink Swann reiterated an “outperform” rating on shares of Intra-Cellular Therapies in a research note on Monday, March 20th. Cantor Fitzgerald set a $29.00 price target on Intra-Cellular Therapies and gave the stock a “buy” rating in a research note on Thursday, May 11th. Cowen and Company reiterated a “buy” rating on shares of Intra-Cellular Therapies in a research note on Wednesday, March 1st. Finally, ValuEngine lowered Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $30.50.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc. (NASDAQ:ITCI).

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.